Key facts
- This page summarizes Mohammad Azab's Form 4 filing for LISATA THERAPEUTICS, INC. (LSTA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 11 Jan 2023, 15:12.
Mohammad Azab - 09 Jan 2023 Form 4 Insider Report for LISATA THERAPEUTICS, INC. (LSTA)
- Reporting relationship
- Director
- Issuer ticker
- LSTA
- Reported as of
- 09 Jan 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Jan 2023, 15:12:19 UTC
- Prior SEC filing
- 13 Dec 2022
- Next SEC filing
- 02 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- James Nisco, Attorney-in-Fact for Mohammad Azab
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mohammad Azab filed Form 4 for LISATA THERAPEUTICS, INC. (LSTA) on 11 Jan 2023.
Change
- Previous filing in this sequence was filed on 13 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LSTA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- +104%
- Price
- $0.000000
- Shares after
- 39,200
- Date
- 09 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents 20,000 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2024.
Footnote F2
Includes 39,200 unvested restricted stock units.